ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma
ADT-1004 has strong antitumor activity in aggressive and clinically relevant PDAC models with unique selectivity to block RAS-mediated signaling in RAS mutant cells. As a pan-RAS inhibitor, ADT-1004 has broad activity and potential efficacy advantages over allele-specific KRAS inhibitors. These findings support clinical trials of ADT-1004 for KRAS mutant PDAC.
Authors
- Jeremy B. Foote (ORCID: https://orcid.org/0000-0002-6621-6096)
- Donald J. Buchsbaum (ORCID: https://orcid.org/0000-0003-2797-5847)
- Asfar S. Azmi (ORCID: https://orcid.org/0000-0003-1178-9505)
- Adam B. Keeton (ORCID: https://orcid.org/0000-0002-3053-341X)
- Upender Manne (ORCID: https://orcid.org/0000-0002-1545-3032)
- Bassel F. El‐Rayes (ORCID: https://orcid.org/0000-0002-2661-5746)
- Julienne L. Carstens (ORCID: https://orcid.org/0000-0001-9914-0430)
- Sujith Sarvesh (ORCID: https://orcid.org/0000-0002-2689-6568)
- Greg Gorman (ORCID: https://orcid.org/0000-0003-4306-8884)
- Dhana Sekhar Reddy Bandi (ORCID: https://orcid.org/0000-0003-0405-5503)
- Gary A. Piazza (ORCID: https://orcid.org/0000-0003-4418-887X)
- Karina J. Yoon (ORCID: https://orcid.org/0000-0002-0830-571X)
- Mehmet Akce (ORCID: https://orcid.org/0000-0003-4747-7722)
- Emily C. Graff (ORCID: https://orcid.org/0000-0002-2141-0864)
- Kristy Berry
- Xi Chen (ORCID: https://orcid.org/0000-0001-9138-1432)
- Sejong Bae (ORCID: https://orcid.org/0000-0001-9982-3223)
- Yu-Hua Fang (ORCID: https://orcid.org/0000-0002-1039-7983)
- Yulia Y. Maxuitenko
- Jacob Valiyaveettil
- M. R. Boyd
- Ganji Purnachandra Nagaraju
Institutions
- University of Alabama (US)
- Wayne State University (US)
- University of Alabama at Birmingham (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Auburn University (US)
- Samford University (US)
Publication Details
- Journal
- Molecular Cancer
- Published
- 2025-03-13
- DOI
- https://doi.org/10.1186/s12943-025-02288-9
- Citations
- 14
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 14.64
Funders
- Auburn University
- National Institutes of Health